Abstract Signal transducer and activator of transcription 3 (STAT3) is aberrantly activated in glioblastoma and has been identified as a relevant therapeutic target in this disease and many other human cancers. After two decades of intensive research, there is not yet any approved STAT3-based glioma therapy. In addition to the canonical activation by tyrosine 705 phosphorylation, concordant reports described a potential therapeutic relevance of other post-translational modifications including mainly serine 727 phosphorylation. Such reports reinforce the need to refine the strategy of targeting STAT3 in each concerned disease. This review focuses on the role of serine 727 and tyrosine 705 phosphorylation of STAT3 in glioma. It explores their contribution to glial cell transformation and to the mechanisms that make glioma escape to both immune control and standard treatment.
Introduction
Gliomas are the most frequent primary adult brain tumors. In 2016, the WHO published a new classification of glioma integrating both histological and biomolecular features [1] . They are classified by histological pattern as astrocytic and oligodendroglial tumors according to the World Health Organization (WHO) classification. The most of adults' gliomas are infiltrative or diffuse tumors which make resection almost always incomplete. Diffuse gliomas are categorized into low-grade glioma (WHO grade II), with slow growth, and high-grade or anaplastic glioma (WHO grades III and IV) that are fast-growing. Glioblastoma (GBM) is the most frequent and malignant type of glioma (grade IV), the most common primary tumors of the central nervous system. Primary GBMs arise de novo while secondary GBMs develop from grades II and III glioma. Primary and secondary GBMs are indistinguishable histologically, but they differ in their genetic and epigenetic profiles [2] . Isocitrate dehydrogenase 1 (IDH1) and less frequently IDH2 mutations are major molecular markers of secondary GBMs [3] . The first line setting of GBM patient treatment encompasses surgery followed by tumor bed irradiation and concomitant and then adjuvant chemotherapy with temozolomide [4] . Despite such a complex therapy, recurrence is unavoidable, due to GBM cell radiochemoresistance [5] and the median survival is nowadays around 14 months. Management of GBM patients at recurrent disease state is not unanimously codified because of an enhanced aggressiveness [6] . Gliomas are one of human cancers in which existence of cancer-initiating cells also called cancer stemlike cells, has been established [7, 8] . Cancer stem cells have self-renewal and tumorigenic capacities and reproduce some but not all stem cells behaviors [9] . Genetic studies using murine glioma models revealed that glioma stemlike cells may arise from neural stem cells that are localized mainly at the ependymal surface of the ventricles [10] . Furthermore, it has been reported that GBM in close proximity to the ependymal surface of the ventricles convey a worse prognosis [11, 12] . Therefore, glioma stemlike cells and their specific features are thought to be involved in glioma genesis, recurrence, and aggressiveness.
Several pathways have been reported as involved in the pathogenesis of GBM [13] . Some of them have been reported as prognostic markers or therapeutic targets. Signal Transducer and Activator of Transcription 3 (STAT3) has been identified as a therapeutic target [14] in glioma because (i) several signaling pathways altered in glioma converge to STAT3 and (ii) it is involved in several hallmarks of glioma aggressiveness, through modulation of genes notably implicated in cell proliferation, growth, apoptosis, migration, invasion, and neoangiogenesis. STAT3 belongs to a protein family encompassing seven members sharing a common structure but largely differing in their functions. It is well established that STAT3 is an intracellular cell signaling protein activated by canonical phosphorylation [15] on its tyrosine 705 residue (pSTAT3-Y705), which induces its transfer to the nucleus for target gene regulation [16] [17] [18] . In addition to glioma, many other human cancers display activated STAT3. Therefore, studying the role STAT3 in cancer provided rational for design of STAT3 inhibitors to be used as anticancer targeted therapy [19, 20] . However, such inhibitors have not yet been approved for treatment of glioma patients because of toxicity or inefficiency. This strengthens the need to refine the strategy of targeting STAT3 in glioma. Furthermore, recent concordant evidences attributed biological functions to post-translational STAT3 modifications other than Y705 phosphorylation, including lysine methylation [21] and acetylation [22] [23] [24] as well as serine 727 phosphorylation (pSTAT3-S727). All these modifications cooperate with or act independently from the canonical pSTAT3-Y705 in regulating STAT3 activity [25] [26] [27] . Existence of such post-translational STAT3 modifications should be taken in account in STAT3-based drug designing. However, investigators did not always assess STAT3 activation through detection of all activated forms, including mainly pSTAT3-Y705 and pSTAT3-S727 together. Understanding the fine regulation of STAT3 in glioma and the role of each of its post-translational modifications in the disease aggressiveness may help improve the therapeutic targeting of STAT3.
After a general description of STAT3 signaling, this review focuses on S727 and Y705 phosphorylation of STAT3 and their involvement in the biological processes that lead to glial cell transformation as well as tumor growth and escape to both immune control and standard treatment.
STAT3 in the STAT Protein Family
The STAT proteins constitute a family of signal transducers and transcriptional regulators. This family encompasses STAT1, 2, 3, 4, 5A, 5B, and 6 [28] . Each of them is encoded by a unique different gene. The STAT proteins are characterized by a common structure (Fig. 1 ) that typically consists of an N-terminal domain, a coiled-coil domain, a DNA binding domain, a linker, an SH2 domain, and a transactivation (TA) domain [29] . The TA domain contains tyrosine and serine phosphorylation sites that are involved in STAT activation. There are truncated isoforms which are generated by alternative mRNA splicing of the single gene transcript of STAT1 [30] , STAT3 [31] [32] [33] , STAT4 [34] , STAT5A [35] , STAT5B [36] , and STAT6 [37] . In addition, isoforms resulting from proteolytic cleavage of STAT3 [38] , STAT5A [39, 40] , STAT5B, and STAT6 [41] have been identified. Most truncated isoforms act as dominant-negative of the corresponding full-length proteins [38, 42, 43] . STAT2, 4, and 6 are mainly involved in immune system regulation whereas STAT1, 3, and 5 play immunological and many other biological functions. STAT3 and STAT5 are hyperactivated in many human cancers where they contribute to cell transformation [44] [45] [46] and to survival and proliferation of transformed cells [47] . Therefore, they have been identified as relevant targets for the development of anticancer therapies [44, 48] .
The gene encoding STAT3 is located in the human 17q21.31 genomic region and is expressed in several cell types [49] . Alternative mRNA splicing and proteolytic cleavage give rise to STAT3α (full-length) isoform consisting in 770 aminoacids and to STAT3β, a 722 aminoacids dominantnegative variant [38] . STAT3 expression is crucial for the embryogenesis, attested by mouse models, since homozygous knock-out of STAT3 resulted in lethal embryonic degeneration at day 6.5-7.5 [50] . Consistently, there is no reported homozygous inactivation of STAT3 in humans, strengthening the requirement of STAT3 in embryonic development.
Heterozygous inactivating mutations by transition, transversion, or punctual deletions in STAT3, mainly located in the DNA binding domain and the SH2 domain, have been associated to Autosomal Dominant Hyper-Immunoglobulin E Syndrome (AD-HIES) previously called Job's syndrome [51] [52] [53] [54] [55] . AD-HIES patients have an elevated IgE level in serum, with an immune deficiency that involves lymphocytes, mainly Th17, Tfh, memory B cells, and TCD8+ cells. They also have a susceptibility to develop B type lymphomas and are exposed to diverse infectious diseases.
Furthermore, gain-of-function mutations in the DNA binding domain or the dimerization domain of STAT3 have been associated to auto-immune disorders that confirmed the involvement of STAT3 in the immune system functional maturation [56, 57] . Functional activation of STAT3 due to punctual mutations in SH2 domain has been observed in chronic lymphoproliferative disorders of NK cells and in T cell large granular lymphocyte leukemia [58, 59] .
General Description of STAT3 Pathway Signaling
The pool of STAT3 in cells is submitted to a fine regulation consisting in several mechanisms. This includes a synthesisdegradation cycle, controlled by proteasome-dependent pathways, that regulates total STAT3 availability [60, 61] . Another mechanism is an activation-inactivation cycle that makes STAT3 activation transient as a rule. Phosphorylation/ dephosphorylation is the best known STAT3 pathway modulating mechanism. This is due to cooperation between finely regulated enzymes which are tyrosine kinases, serine/ threonine kinases, and many phosphatases [62] . Phosphorylation is prior to nuclear translocation and subsequent gene expression modulation. The main conserved signaling pathways driving STAT3 phosphorylation are summarized in Fig. 2 .
From STAT3-Y705 Phosphorylation to Dimerization and Transcription Activation
At its discovery in 1994, STAT3 was described as an acutephase response factor activated in response to cytokines that induce signal through the gp130 transmembrane protein.
Those cytokines include interleukin-6 (IL-6), leukemia inhibitory factor (LIF), oncostatin M (OSM), and the ciliary neurotrophic factor (CNTF) [63, 64] . Upon phosphorylation of gp130, STAT3 is recruited to the gp130 cytoplasmic region by interaction with its SH2 domain. To phosphorylate the Y705 residue of STAT3, the receptor complex recruits a member of Janus kinase (JAK) family of cytoplasmic kinases including JAK1, JAK2, JAK3, and TYK2. Among them, JAK2 is the main STAT3-Y705 activator (Fig. 2) .
Plasma membrane receptors carrying an intrinsic intracellular protein-tyrosine kinase activity may also trigger STAT3 phosphorylation of the Y705 residue. These include growth factor receptors such as the EGFR [65, 66] and PDGFR [67] .
Besides intrinsic and extrinsic activity involving cellsurface cytokine receptors, pSTAT3-Y705 can be induced directly by some cytoplasmic kinases including the Src family [68] , Bone Marrow X-linked (BMX [69, 70] ) and the Bcr-Abl fusion protein [71, 72] .
Two pSTAT3-Y705 associate to form active dimers capable of translocating to the nucleus. Therein, they interact with specific response element consisting in TTN 4-5 AA consensus DNA sequences called interferon gamma-activated sequences (GAS). They therefore induce transcription of specific target genes [16, 17] (Fig. 3) .
Serine 727 Phosphorylation and Other Post-Translational Modifications of STAT3
In addition to Y705 phosphorylation, STAT3 is also activated by serine 727 phosphorylation. The functions and the kinases responsible for S727 phosphorylation of STAT3 have been discussed during the last two decades [73] [74] [75] . S727 phosphorylation is achieved by serine/threonine kinases that are members of the protein kinase C (PKC) family such as PKC-δ [76] , PKC-ε [77] [78] [79] . Cyclin-dependent kinase 5 was recently shown to interact and phosphorylate STAT3-S727 [80] . Other kinases downstream the MAP kinase pathway [73, 74, 81] and the NOTCH pathway [25] have also been reported as involved in STAT3-S727 phosphorylation (Fig. 2) .
Recent studies provided evidence that the biological function and the regulation of pSTAT3-S727 depend on cell type and cell differentiation state [26, 27, 82, 83] . Considering together the published data, it becomes clear that STAT3 plays a critical role in the control of many cellular processes (Fig. 3) . However, the contribution of each of pSTAT3-Y705 and pSTAT3-S727 in those processes remains unclear because authors did not use methods that allow such distinguishing. In the light of the current knowledge, one can hypothesize that some genes are preferentially regulated by only one or both pSTAT3-Y705 and pSTAT3-S727. In case of involvement of both phosphorylations, their action could be consistent or not. For instance, results reported by Xu et al. provided evidence that knockdown of PKCε attenuates pSTAT3-S727 and expression of Bcl-XL but not that of Bcl-2 which is another STAT3 downstream target. The authors hypothesized that knockdown of PKCε may influence signaling pathways that may compensate each other in regulating Bcl2 expression [79] . We further speculate, because pSTAT3-Y705 was unaffected by PKCε inhibition, that it may have maintained Bcl-2 expression.
In addition to phosphorylation, concordant evidences attributed biological functions to other post-translational modifications of STAT3 including lysine methylation [21] and acetylation [22] . Such modifications require further investigation to decipher their role in the STAT3 cascade.
STAT3 Pathway Downregulation by Tyrosine Phosphatase Activity
The identified phosphatases involved in the dephosphorylation of pSTAT3-Y705 belong to a family of receptor-type phosphatases and to a group of non-receptor (intracellular) Fig. 2 Conserved signaling pathways driving STAT3 phosphorylation. pSTAT3-Y705 is induced downstream gp130 phosphorylation and JAK2 recruitment. Activated JAK2 can be inhibited by SOCS3. Activated EGFR or its mutated versions including EGFRvIII induce pSTAT3-Y705. pSTAT3-Y705 can also be induced by intracellular kinases like BMX. PTPRD dephosphoylates pSTAT3-Y705 whereas PIAS3 directly inhibits activated STAT3. pSTAT3-S727 is directly mediated by PKCε or through an unknown mechanism (discontinuous arrow) downstream the NOTCH1 pathway activation. Activated STAT3 homodimerise translocate to the nucleus and interact with GAS for target gene regulation. They upregulate expression of several genes, including HIF1α, VEGF, SOC3, and IL-6. The released IL-6 contributes to autoand paracrine activation of its pathway. pSTAT3-Y705 can interact with NF-κB (p65). STAT3-NFκB oligomers bind to DNA and regulate several target genes, including Jagged 1 that encodes a NOTCH1 ligand. In the absence of the Notch Intracellular Domain (NICD), the DNA-bound RBPJ acts as a gene transcription repressor. Its interaction with the NICD switches it to a co-activator of gene expression protein-tyrosine phosphatases. The category of receptor-like phosphatases includes mainly the receptor-type tyrosine-protein phosphatase delta (PTPRD) [84, 85] and the receptor-type tyrosine-protein phosphatase O (PTPRO) [86] that are enzymatic transmembrane proteins. The inhibiting pSTAT3-Y705 intracellular phosphatases are members of the protein-tyrosine phosphatase non-receptor (PTPN) family including PTPN1 (or PTP1B) [87] , PTPN2 (or TC-PTP) [88, 89] , PTPN6 (or SHP1) [90, 91] , PTPN9 (or PTPMeg2) [92, 93] , PTPN11 (or SHP2) [94] , and PTPN12 [95] .
It was reported that pSTAT3-S727 activates TC45, a nuclear PTPN2 isoform to dephosphorylate pSTAT3-Y705 [96] . Therefore, TC45, may provide an explanation to a kind of a STAT3 autoregulation system described in an early study of STAT3 showing that pSTAT3-S727 negatively regulates pSTAT3-Y705 [73] . More recent investigations demonstrated that PASD1 protein competed with TC45 to associate with STAT3, blocking thus TC45-mediated dephosphorylation of STAT3. PADS1 serves therefore as a critical nuclear positive regulator of pSTAT3-Y705 [97].
STAT3 Pathway Downregulation by Serine/Threonine Phosphatase Activity
Besides protein-tyrosine phosphatases, STAT3 dephosphorylation also involves protein serine/threonine phosphatases, mainly the phosphoprotein phosphatase 2A (PP2A) [62, 98, 99] . Activity of such phosphatases on STAT3 is regulated by other STAT3 interacting proteins like the STAT3-Interacting Protein As a Repressor (SIPAR) that promotes dephosphorylation of pSTAT3-Y705 [100] and like 14-3-3ζ, a protein that protects pSTAT3-S727 from dephosphorylation by PP2A [99] . It has also been reported that a non-coding long RNA called Inc-DC interacts with STAT3 in dendritic cells and prevents fixation of SHP1 protein-tyrosine phosphatase [101] .
Other Mechanisms Modulating STAT3 Pathway
The fine regulation of STAT3 activity also involves the Protein Inhibitor of Activated STAT3 (PIAS3) that is an E3 SUMO-protein ligase [102, 103] that directly blocks activated [102] . It moreover includes modulation of STAT3 upstream kinases such as the inhibition exerted by the suppressor of cytokine signaling (SOCS) on the JAK protein family [104] . Lately, Lee et al. described that the endogenous transmembrane protein upstream-of-mTORC2 (UT2) interacts directly with gp130 and inhibits phosphorylation of STAT3-Y705 [105] .
STAT3 is also submitted to a cytokine-induced acetylation and deacetylation process mediated on its SH2 domain lysine K685 respectively by p300 and type I HDAC family members [24] . K685 acetylation induces stable dimer formation required for cytokine-stimulated DNA binding and gene transcription regulation. K685 acetylation is also critical for functional regulation of STAT3 lacking Y705 phosphorylation [106] . Acetylation of the STAT3 coiled-coil domain on the K49 and K87 lysines has been reported. These modifications are also controlled by p300 and type I HDAC family members. However, functional analysis showed that unlike K685 acetylation, they are not involved in STAT3 dimerization and translocation to the nucleus, but they are required for IL-6-induced gene transcription [23] .
Activated STAT3 is also regulated by methylation on K140 by the histone methyltransferase SET9 and by demethylation mediated by LSD1 [21] . K140 methylation of STAT3 is a negative regulator of transcription activation by promoter b ou nd S TAT 3 . F u r t h er m or e, ph o s ph or yl ate d or unphosphorylated STAT3 [107] physically interact with various other transcription factors thus contributing to their functional regulation. These include STAT1 [108] , the Sp1 transcription factor [109] , PPAR-γ [110] , Smad1 [111] , the androgen receptor [112] , nuclear factor κB (NF-κB) [113] , and cJun [114] . Since the STAT3 pathway regulation is complex, a precise description of activated patterns and causal mechanisms in each concerned disease should be helpful in designing STAT3-based therapy.
The Mechanisms Leading to STAT3 Activation in Human Glioma Cells Activation of Protein-Tyrosine Kinases
There is not any identified gain-of-function mutation of human STAT3 in glioma; the constitutive activation of STAT3 in this disease is therefore due to an aberrant signal from upstream regulators. This includes, on one hand, any gain-offunction mutation or increase in activation of an upstream activator, and, on the other hand, any loss-of-function mutation or any decrease in activation of an upstream repressor. The first group involves mainly alterations in the EGFR signaling pathway and those in the IL-6 signaling axis. Both pathways are induced by receptor-associated tyrosine kinase activities. Gene amplification and/or rearrangements that result in the EGFRvIII truncated variant of EGFR, or the EGFR-SEPT 14 fusion mutant of EGFR, induce an aberrant, excessive signal leading to a hyperactive pSTAT3-Y705 [115, 116] . Insulin-like growth factor binding protein 2 (IGFBP2) augments the nuclear accumulation of EGFR to potentiate STAT3 transactivation activities, via activation of the nuclear EGFR signaling pathway [117] .
In addition to or independently of EGFR activation, IL-6 participates in complex genetic and epigenetic regulatory circuits that orchestrate STAT3 constitutive activation in glioma [118] . We have reported IL-6 overexpression in GBM patients and cell lines [119, 120] . IL-6 induces STAT3 activation by a signal transduced through a hexameric transmembrane receptor complex that implicates the IL-6Rα (gp80) and the gp130 subunits and that is shared with receptors of other cytokines such as IL-11, LIF, CT-1, CTNF, OSM, and CLC [121] . Among them, OSM plays, as IL-6, a critical role in glioma [122, 123] . OSM mainly contributes to the aggressiveness of the mesenchymal subtype of glioma [124] . OSM receptor (OSMR) was reported to form a complex with EGFRvIII. This complex activates STAT3 and upregulates OSMR expression. The result is a feed-forward signaling mechanism that drives oncogenesis [125] . IL-6-induced STAT3 activation was usually assessed by monitoring pSTAT3-Y705 [126] . But Liu et al. reported a dose-dependent increasing accumulation of pSTAT3-S727 in T98G and U251 human GBM cell lines treated by various concentrations of IL-6 [127] . In that assay, variation of pSTAT3-Y705 has not been evidenced. To our knowledge, such demonstration has not yet been reproduced. We used IL-6 blocking antibodies to challenge GBM cells, and it resulted in a decrease in pSTAT3-Y705 while pSTAT3-S727 remained stable (unpublished data). Apart from gp130 signaling chemokines, IL-22, hypothetically secreted by stromal cells, was reported to activate pSTAT3-Y705 in glioma cells [128] . Moreover, it has been shown that STAT3 activation increased transactivation of VEGF promoter and VEGF secretion by GBM cells [129, 130] . In addition to those pathways, pSTAT3-Y705 can be induced through signal induced by many other cytokines or growth factor receptors such as PDGFR, depending on cell type or experimental conditions [131] .
Besides its induction by receptor-associated tyrosine kinase activity, activation of STAT3 in glioma can also be triggered by non-receptor tyrosine kinases. This implicates intracellular kinases such as BMX which is expressed by some GBM stemlike cell subpopulation [132] . Since knocking down BMX impaired pSTAT3-Y705 accumulation, it has been described as an upstream activator of STAT3 in GBM stemlike cells.
Activation of Protein Serine/Threonine Kinases
Serine/threonine kinases are intracellular proteins that can mediate STAT3 activation by phosphorylating its serine 727 residue. The serine/threonine kinase protein kinase C epsilon (PKCε) is overexpressed in human anaplastic astrocytoma, GBM, and gliosarcoma and is associated to a worse disease prognosis [133] . This overexpression of PKCε has been shown to take part in the constitutive activation of STAT3 through serine 727 phosphorylation in several human glioma cell lines [77, 79] .
The NOTCH pathway has been implicated in STAT3 activation since it has been shown that NOTCH signaling stimulation by Delta-like 4 (Dll4) and Jagged 1 (Jag1) NOTCH ligands promotes human embryonic stem cell survival through STAT3 serine 727 phosphorylation [134] . This NOTCH-mediated effect on normal stem cell fate can be blocked by the NOTCH pathway inhibitor DAPT, a gammasecretase inhibitor that impairs activating cleavage of NOTCH by Presenilin 1. Moreover, the preponderant role of NOTCH in activating STAT3-S727 in glioma became evident when Fan et al. demonstrated that blocking the activated NOTCH pathway in GBM stemlike cells by Gamma-Secretase Inhibitor 18 (GSI-18) reversed accumulation of pSTAT3-S727 and furthermore selectively impeded cell proliferation [25] . Those findings suggest that there is a regulation loop involving activated STAT3 and NOTCH signaling because the NOTCH pathway regulates pSTAT3-S727 and pSTAT3-Y705 participates with NF-κB in regulating activated NOTCH signaling in GBM stemlike cells [135] . More studies should help decipher this regulatory loop in GBM stemlike cells.
Deficiency in Upstream Repression of STAT3
Apart from an increased activity of an upstream activator, any loss-of-function mutation or any decrease in activation of an upstream repressor may explain the constitutive activation of STAT3 in glioma. This second group of deregulating mechanisms involves the PIAS3, the SOCS, and PTPRD.
Concordantly with pSTAT3-Y705 and pSTAT3-S727 overexpression, the PIAS3 is less expressed in GBM in comparison with non-neoplastic brain tissue [136] . Furthermore, inhibition of PIAS3 in U87-MG human glioma cell line by RNA interference boosted cell proliferation despite no or little change in the level of phosphorylated STAT3. Conversely, overexpression of PIAS3 in U251-MG human glioma cell line dumped OSM-enhanced expression of the STAT3 targeted genes Survivin, Bcl-xL as well as SOCS3 and resulted in 80 % slow-down of cell proliferation [136] .
The SOCS protein family includes cytokine inducible signal transducers that encompass several members involved in negatively regulating cytokine and growth factor-induced signal [137] . Among them, SOCS3 is not only a STAT3 target gene but also an upstream repressor of STAT3 via its inhibitory action on JAK kinases [138] . Thus, SOCS3 functions in a negative feedback loop to regulate STAT3 activity. GBM tumors and cell lines overexpress SOCS3 whereas they repress SOCS1 [136, 139, 140] . This aberrant expression of SOCS3, concomitant with a constitutive activation of STAT3, suggests that SOCS3 is induced by the STAT3 pathway [140] even if SOCS3 might fail in inhibiting STAT3 in GBM. Further study should help understand the link between the constitutive silencing of SOCS1 and activated STAT3.
PTPRD belongs to a family of protein-tyrosine phosphatases which are involved in the regulation of many normal and cancer cell processes, such as adhesion, proliferation, and migration, through the regulation of multiple cellsignaling pathways [85] . PTPRD function is frequently inactivated by genetic and epigenetic alterations in GBM as well as in other cancers, and is associated to a worse patient prognosis [141, 142] . Functional analysis in mice, recently published by Ortiz et al., showed that loss of heterozygoty of PTPRD resulted in accumulation of pSTAT3-Y705 and cooperated with CDKN2A/p16
IN4KA to promote glioma tumorigenesis [143] .
Other STAT3 Activating Mechanisms
Apart from deregulation of upstream regulators, other factors cooperate in inducing hyperactivity of STAT3 in glioma. Some of them have been identified but more studies are required to well characterize the mechanisms of their action. This is the case of the mutation in the GDNF Family Receptor Alpha 4 (GFRA4) gene exon 2 that induces mislocated weakly interacting GFRA4-persephin (PSPN) complexes. These complexes aberrantly dissociate from the RET proto-oncogene product (RET) at the plasma membrane and relocate to the endoplasmic reticulum [144] . Moreover, GFRA4 silencing or artificial redirection of GFRA4 to the plasma membrane reduced pSTAT3-Y705 and resulted in slowed glioma cell proliferation.
Evidence and Prognostic Value of STAT3 Activation in Glioma Specimens

Phosphorylation of STAT3-Y705
Phosphorylated STAT3 has been detected by immunohistochemistry assays performed on frozen or paraffin-embedded glial tumor sections and by immunoblotting of tumor tissue samples. The early studies reported positive detection of pSTAT3-Y705 in a variable proportion of glioma of the studied cohorts [116, [145] [146] [147] [148] . This variability might be due to the cohort size and to the limits of sensitivity and specificity of the diagnosis and of the detection methods. Moreover, comparison of the published results should consider that the cut-off point of positive detection was different. The detected pSTAT3-Y705 was located in the nucleus of a variable number of glial tumor cells or tumor-associated lymphocytes or vascular endothelial cells [116, 146, 148] . Normal brain tissue was negative for pSTAT3-Y705 staining except in one over five specimens reported by Lo et al. [116] . Considering the group of specimens in which the section showed more than 20 % pSTAT3-Y705 positively stained cells, Lo et al. found a positive correlation of pSTAT3-Y705 and glioma grade. However, in a cohort of 111 GBM (WHO grade IV glioma) cases and 25 WHO grade III gliomas, Birner et al. did not find any correlation with the disease grade among cases that showed more than 5 % positive cells [149] . Using other methods such as electrophoretic mobility shift assay and Western blotting, greater proportions of pSTAT3-Y705 expressing tumors or higher levels of pSTAT3-Y705 have been positively correlated to glioma tumor grade [136, 150] .
Constitutive Phosphorylation of STAT3-S727
The detection of serine pSTAT3-S727 in U87-MG and U373-MG glioma cell lines has been achieved by Western blot showing STAT3 inhibition that accompanied cell death induced by telomere 3′ overhang-specific DNA oligonucleotides [151] . The first description of serine pSTAT3-S727 in glioma tissues has been reported by Brantley et al. [136] . Two years later, this constitutive activation of STAT3-S727 has been confirmed in patient-and cell line-derived GBM stemlike cells [25, 27] . This study of Villalva et al. evidenced that STAT3 was activated in GBM stemlike cells mainly through pSTAT3-S727. Moreover, disruption of STAT3 activity impaired proliferation and neurosphere formation. Recently, pSTAT3-S727 has been described by immunohistochemistry in 70.5 % of 88 GBM cases [152] . Even though pSTAT3-S727 was found in the cytoplasm, the main subcellular location was the nucleus of the neoplastic cells and some vascular endothelial cells. Normal brain tissue did not show any expression of pSTAT3-S727. Moreover, this study of Lin et al. evidenced a statistically significant association of pSTAT3-S727 and pSTAT3-Y705 [152] . In a cohort of 30 GBM clinical specimens and a panel of 15 GBM cell lines, we showed that pSTAT3-S727 is present in all studied human malignant glioma cell lines and all the examined GBM specimens [153] . However, pSTAT3-Y705 was not detected in some GBM cell lines or specimens and was moreover restricted to a variable number of GBM cells in the positive clinical samples. These results are consistent with an involvement of pSTAT3-S727 in the process of oncogenesis as a driving mechanism as suggested for mouse hepatocarcinomas [82] or as a consequence of cell transformation. Analysis of these two phosphorylations in relation with tumor grade might help to confirm or infirm this hypothesis.
STAT3 and Prognosis
Many studies have examined the prognostic value of STAT3 expression and activation in glioma. Early studies of the signaling pathways activated downstream EGFR, including MAPK, Akt, and STAT3, established that pSTAT3-Y705 is correlated to the presence of the EGFRVIII muted variant of EGFR in anaplastic astrocytoma and GBM [147] . Among those downstream effectors of the EGFR pathway, MAPK and Akt but not STAT3 have been correlated to the progression of grade III astrocytoma to GBM (grade IV). In accordance, activated Akt but not pSTAT3-Y705 was predictive of a worse glioma prognosis.
In opposition to Mizoguchi et al. who evaluated STAT3 activity by quantifying pSTAT3-Y705 in tumors, Alvarez et al. assessed functional activation of STAT3 through expression of a subset of 12 genes admitted as defining the STAT3 signature [154] . This study found a positive correlation linking high expression level of STAT3 target genes with a poorer prognosis in glioma. However, they did not correlate phosphorylated STAT3 with gene expression in tumor samples. Another study established that pSTAT3-Y705 was a negative prognostic marker in anaplastic astrocytoma [145] . Furthermore, some other studies reaffirmed the bad prognostic value of the constitutive activation of pSTAT3-Y705 alone or in association with others mesenchymal markers such as C/EBP-β and C/EBP-δ in GBM [155, 156] .
The bad clinical meaning of STAT3 activation has recently been attested by the studies carried out by Lin et al., which established that a high number of pSTAT3-Y705 and pSTAT3-S727 positive cells in GBM specimens, independently of each other, impact negatively the patients' progressionfree survival and overall survival [152, 157] . Moreover, increased expression of the both makes worse the clinical outcome [152] . Since, pSTAT3-Y705 is not detected is some glioma specimens and does not accumulate in all glioma neoplastic cells [153] , we speculate that it is not a major driver of GBM aggressiveness. In contrast, pSTAT3-S727 detected is all neoplastic cells of all GBM specimens may be a best prognostic marker, provided that a discriminative detection assay is performed.
Role of STAT3 in Glioma Tumorigenesis and Aggressiveness
After phosphorylation and dimerization, STAT3-dimers translocate into the nucleus where they modulate expression of targeted genes harboring GAS sequences. STAT3 is involved in cell transformation but could also act in tumor cell including GBM stemlike cells to promote aggressiveness and resistance to current therapies. Thus, STAT3 signaling modulates expression of several genes implicated in transformation, survival, proliferation, immunosuppression, migration, invasion, and neoangiogenesis (Fig. 3) .
STAT3 in Glioma Genesis
The first demonstration of STAT3 involvement in cell transformation rose from the observation that it was activated through pSTAT3-Y705 in fibroblasts and epithelial cells, which have been stably transformed by the Src oncogene tyrosine kinase [68] . Moreover, transgenic mice expressing vsrc under control of GFAP gene regulatory elements developed transplantable astrocytoma that progress to GBM, thus providing evidence of the involvement of v-src and probably the consecutive activated STAT3 in initiating and promoting glioma genesis in a multistep way [158, 159] . Consistent with the implication of activated STAT3 in the tumorigenesis of glioma, another analysis have evidenced that malignant transformation by v-src and maintenance of transformed phenotype require STAT3 that is however dispensable for normal cell growth [160] . The genuine oncogenic function of STAT3 by its own became clear with functional analysis using interfering negative or positive STAT3 dominant proteins. Negative dominant mutants rendered cells refractory to v-src transformation [81, 161] whereas positive dominants induced by themselves carcinogenesis [162, 163] . The involvement of STAT3 in tumorigenesis is further explained by studies showing that pSTAT3-S727 localizes in the mitochondria of diverse cell types and sustain cellular functions including mitochondrial gene regulation [164] , viability [165] , and cell transformation [166] . However, a report demonstrated that STAT3 activation in glioma can also play a tumor suppressor function depending on tumor genetic background mainly on the mutational status of PTEN [167] . Rat orthotopic glioma models generated with the STAT3 S727A mutant (inactivated STAT3-S727) cell line resulted in more aggressive tumors in comparison to the STAT3 WT expressing stable cell line tumors [62] . However, interpretation of such results should take in account an obvious concomitant increase in pSTAT3-Y705 level in the STAT3 S727A tumor cells. This increased pSTAT3-Y705 may be sufficient to boost tumor aggressiveness in the STAT3-S727A mutant. Concurrently, modulating S727 and Y705 is essential in deciphering the contribution of both in tumorigenesis.
STAT3 Function in Cell Survival and Proliferation
Inhibition of the STAT3 pathway by various strategies resulted in a decreased accumulation of antiapoptotic gene products such as Survivin, Bcl-XL [168] , Bcl-2, and Mcl-1 [169] (Fig. 3) . In addition, inhibiting activated STAT3 reduced expression of cell cycle regulators: c-myc, cyclin D1, and cyclin E [170] . Those experiments have been conducted in vitro [169] as well as in vivo [170, 171] . Through control of regulators of cell cycle and apoptosis, inhibiting STAT3 activity resulted in increased cell death and decreased cell or tumor growth. Since STAT3 activity has been modulated by targeting pSTAT3-Y705 (pharmacological inhibitors, blocking antibodies, and dominant-negative proteins) or total STAT3 protein accumulation (RNAi) or STAT3 dimers formation or binding to DNA (decoy oligonucleotides), the role of pSTAT3-S727 remained misunderstood in the cell fate control by STAT3. Interestingly, inhibiting STAT3 dimer formation and DNA binding by the mean of STA-21, S3I-201 [83] , hydroxamic acid-based (SH5-07), and benzoic acid-based inhibitors (SH4-54) [172] STAT3 inhibitors which target the STAT3 SH2 domain resulted in apoptosis or decreased cell proliferation (assessed by low BrdU incorporation). This depended on the state of cell differentiation, on the cell culture conditions, and on the profile of STAT3 phosphorylation (pSTAT3-Y705 or pSTAT3-S727). MicroRNA-506 (miR-506) and MicroRNA-519a (miR-519a) have been reported to act as tumor suppressors and inhibit cell proliferation in glioma by targeting STAT3 mRNA and decreasing expression of STAT3 target genes [173, 174] . Any specific pSTAT3-S727 inhibitor should help in understanding the interference of pSTAT3-S727 and pSTAT3-Y705 in the control of cell survival and proliferation.
Regulation of cell survival by STAT3 is tightly linked to blocking of both apoptosis and autophagy since inhibiting active STAT3 by several means induced autophagy and concomitantly sensitized glioma cells to induction of apoptosis [175, 176] . These findings suggested that autophagy contributes to glioma escape to anticancer therapy.
STAT3 Activation Role in Glioma Cell Migration and Invasion
The use of inhibitors of STAT3 upstream regulators pointed that STAT3 might be involved in glioma cell migration and invasion [173, 174, 177, 178] . This inhibition of STAT3 has been linked to downregulation of matrix metalloproteinase gene expression such as MMP2 [179] , MMP9, and to epithelial-mesenchymal transition regulating genes like Snail [180] (Fig. 3 ). STAT3 has also been shown to cooperate with other transcription factors such as NF-κB (p65) [181] and nuclear factor I-X3 [182] in upregulating respectively ICAM-1 and YKL-40, resulting in promotion of glioma cell migration and invasion.
Role of STAT3 Activation in Local Immune Suppression
STAT3 activation has been shown in several models to promote cancer cell immune escape by disturbing the processes involved in normal functioning of both innate and adaptive immune system components. Through plasma membrane interactions [183] and released cytokines such as IL-6, IL-8, IL-10, IP-10 (CXCL10), RANTES, TNFα [184] , TGFβ, and the PGE-2 prostaglandin [185] , STAT3 activation in glioma cells including cell lines, primary cultured cells, and cancer stem cells has been shown in inducing immune tolerance. Through a mechanism that is not fully understood, STAT3 activation in glioma cells blocks differentiation, maturation, and function of dendritic cells, inhibits T cell proliferation [186] (Fig. 3) , induces T cell anergy, T regulatory cells, and immunosuppressive microglia [187] . An explicative mechanism is provided by the demonstration that activated STAT3 in glioma stemlike cells makes them secrete cytokines that induce paracrine activation of STAT3 in immune cells, thus contributing to their functional inactivation [188] . Furthermore, a very recent work established that glioma stemlike cells produce IL-6 and IL-10, which activate B7-H4 expression in tumor infiltrating macrophages through STAT3 signaling. B7-H4 expression in the tumor microenvironment, surrounding the stroma and invasive edge, may contribute to the neoplastic cell escape from immune surveillance by blocking T cell function [189] . Glioma-induced immunosuppression is potentiated by hypoxia [190] . It can be hampered or reversed by STAT3 inhibition [186, 191] , suggesting the relevance of using STAT3 inhibitors in glioma immunotherapy. However, inhibition of STAT3 did not prevent IL-6-induced suppression of Langerhans cell differentiation [192] , indicating that STAT3 activation is not the only one mechanism of glioma-induced immune tolerance. Combined inhibition of STAT3 and p38 MAPK pathways is therefore proposed as a synergic anticancer immunotherapeutic approach [185] . The role of STAT3 in tumormediated immune suppression has been recently reviewed by Fergusson et al. [193] .
Contribution of STAT3 Activation in Glioma Angiogenesis
Through pSTAT3-Y705, STAT3 upregulates VEGF expression in glioma tumor cells in vitro and in vivo [129, 194] . The role of pSTAT3-Y705-induced VEGF expression in glioma angiogenesis and tumor growth is confirmed since U87 human GBM cells expressing dominant-negative STAT3 induced slowly growing tumors with impaired neoangiogenesis [171] . More recently, this was confirmed by the antiangiogenic effect of the JSI-124 JAK-STAT chemical inhibitor [195] . Furthermore, it has been shown that angiogenesis in glioma is accompanied by VEGF-A-induced loss of calpastatin (CAST) in endothelial cells. This downregulation of CAST triggers μ-calpain-induced proteolysis of SOCS3 and subsequent hyperactivation of STAT3 which stimulates transcription of VEGF-C. Induced VEGF-C and VEGF-A act synergistically in angiogenesis [196] . Moreover, elevated ROS production plays a crucial role for STAT3 activation and for angiogenesis in hypoxic glioblastoma cells since blocking ROS resulted in STAT3 inhibition [197] . Clinical trials regarding antiangiogenic therapy with bevacizumab [198, 199] , an anti-VEGF monoclonal antibody approved by the US Food and Drug Administration (FDA) in recurrent glioma patient treatment, and chemical inhibitors of VEGFR such as cediranib [200, 201] did not exhibit the expected benefit in terms of both safety and overall survival prolongation. Those unexpected results suggest that it might be relevant to integrate the modulation of STAT3 in the strategy of antiangiogenic therapy because of its function, at least in part, as upstream regulator of not only angiogenesis, but also autophagy and hypoxia-induced biological effects [14, 175] .
Role of STAT3 in Glioma Stemlike Cell Maintenance
GBM-derived stemlike cells displaying pSTAT3-Y705 and pSTAT3-S727 showed a modified pattern of STAT3 phosphorylation when grown in different conditions [83] . Using Stattic, an SH2 domain inhibitor, Villalva et al. showed that disruption of STAT3 function impaired neurosphere formation by slowing cell proliferation and inducing apoptosis of GBM stemlike cells [27] . STAT3 pathway phosphorylation on S727 or Y705 has been reported to be essential in the maintenance of not only the capacity of these stemlike cells to initiate neurospheres but also their multipotency [25, 83] and their i m m u n o s u p p r e s s i v e a b i l i t y [18 6] (Fig. 3 ) . The carcinoembryonic antigen-related cell adhesion molecule Ceacam1L was described as a crucial factor in glioma stemlike cell maintenance and tumorigenesis by activating cSrc/STAT3 signaling [202] . In addition, pigment epitheliumderived factor (PEDF) has been identified as an EGFRvIII-STAT3-induced autocrine factor that promotes stemness of glioma stemlike cells [203] . The work of Talukdar et al. highlighted that pSTAT3-Y705-nanog signaling mediates the MDA-9/Syntenin (SDCBP) scaffold protein-controlled stemness of GBM stemlike cells while the NOTCH1/c-Myc pathway governs the survival [204] . Mesenchymal stem cells isolated from human glioma sustain stemness of GBM stemlike cells by stimulating the IL-6/gp130/STAT3 axis in a coculture assay [205] . Therefore, GBM stemlike cell stemness generation and maintenance involve complex dialog between tumoral cells and stromal cells in which pSTAT3 isoforms are undoubtedly implicated. Such findings enhanced the need of STAT3 inhibitors because of relevance in targeting both tumoral cells including stemlike cells and stromal cells.
Role of STAT3 Activation in Glioma Resistance to Standard Treatment
Treatment of malignant glioma is based on surgery, radiotherapy, and concomitant and adjuvant chemotherapy with temozolomide [4] . This standard treatment has been reported to prolong patient survival and to delay disease progression [206] . Despite this gold treatment, recurrence is still unavoidable in GBM and recurrent GBM are chemoresistant, mainly due to a selection of resistant tumor clones [6, 207] .
The DNA-repair enzyme MGMT has been identified as conferring resistance to temozolomide. Repression of its encoding gene mainly by promoter methylation in tumors is a predicting factor of GBM response to alkylators [208, 209] . GBM, the highest degree of glioma malignancy, harbor a high level of STAT3 activation. This suggests an involvement of the STAT3 pathway in glioma progression and a possible link with resistance to treatment. This is strengthened by a report showing that recurrent astrocytic glioma displayed an increased STAT3 protein accumulation compared to primary astrocytic tumors [210] .
The involvement of the canonical pSTAT3-Y705 and/or the so far less studied pSTAT3-S727 in resistance to treatment is not yet well defined. Therefore, published data are often incomplete because only one of the two phosphorylations (mainly pSTAT3-Y705) is assessed by authors resulting sometimes in contradictory results. Lee et al. reported an increase in total STAT3 and pSTAT3-S727 accumulation and a concomitant decrease in pSTAT3-Y705 in selected temozolomideresistant cells, independently of MGMT expression, compared to (isogenic) parental [211] . Kohsaka et al. found that downmodulating STAT3 activity by shRNA or chemical inhibitor of pSTAT3-Y705 resulted in attenuated resistance to temozolomide and concomitant decrease in MGMT accumulation [146] . One explanation is the fact that temozomlomide resistance may not be governed only by MGMT. Such observations lead us to hypothesize that pSTAT3-Y705 and pSTAT3-S727 are two alternative drug resistance mechanisms in GBM. STAT3 could affect chemoresistance via Y705 phosphorylation and MGMT expression or via S727 phosphorylation and other unknown mechanisms. It has also been reported that impairment of temozolomide resistance by inhibition of pSTAT3-Y705 is mediated at least in part through modulation of pAkt and β-catenin [212] . Thus, increased STAT3 activity by protein accumulation and/or increased level of pSTAT3-S727 or pSTAT3-Y705 is involved in temozolomide resistance induction through complex mechanisms including upregulation of MGMT, pAkt, and β-catenin activities. Further experiments are really needed to decipher implication of STAT3 signaling in temozolomide resistance.
Besides temozolomide resistance, STAT3 activation is involved in resistance to radiation since suppressing pSTAT3-Y705 activity by resveratrol weakened radioresistance and tumorigenic capacity of GBM cancer stemlike cells [213] . This is strengthened by the recent demonstration by Yuan et al. that suppression of autophagy augments the radiosensitizing effect of STAT3 inhibition in U251 GBM cells [175] . Irradiation-induced proneural-to-mesenchymal transition was also associated with activation of the STAT3 transcription factor, and the combination of pSTAT3-Y705 blockade using JAK2 inhibitors with radiation abrogated the mesenchymal transition and extended survival of in vivo glioma models [214] . We had however previously reported that inhibition of pSTAT3-Y705 by the mean of anti-gp130 neutralizing antibodies or by JSI-124 JAK-STAT chemical inhibitor did not circumvent SF763 GBM cell line radioresistance [215] . Conversely, Gö6976, a multiple kinase inhibitor, downregulated pSTAT3-S727 and significantly reduced intrinsic radioresistance of some human GBM cell lines in which STAT3-Y705 was not activated [153] . Taken together, our results and the recent data suggest that the contribution of activated STAT3 (Y705 and/or S727) in GBM cell radioreresistance depends on cell type and/or on cell differentiation state. Specific inhibitor of pSTAT3-S727 may help highlight the contribution of each of STAT3-S727 and STAT3-Y705 phosphorylation in GBM response to radiotherapy. A relevant hypothesis is that pSTAT3-S727 might drive intrinsic radioresistance whereas pSTAT3-Y705 might sustain resistance due to tumor cell interaction with their microenvironment.
Future Directions to Improve Glioblastomas Patients Treatment by STAT3 Targeting
Understanding the mechanisms involved in the STAT3 pathway regulation is a current interest in the research for GBM therapy. Because pSTAT3-Y705 and pSTAT3-S727 have been reported as GBM markers that sustain some pathological processes of the genesis and of the aggressiveness of this disease, STAT3 inhibitors have been suggested as anticancer targeted therapeutic agents. Many pSTAT3-Y705 inhibitors have been engaged in clinical trials but there is not yet a proposed therapeutic pSTAT3-S727 inhibitor. However, recent data suggested that pSTAT3-S727 but not pSTAT3-Y705 is a constant pathological feature of activated STAT3 involved in the GBM resistance to gold standard therapy. These results underline the relevance of a combined inhibition of both pSTAT3-S727 and pSTAT3-Y705 in GBM therapy to counteract STAT3 pathological activation in glioma cells, glioma stemlike cells, and stromal cells.
Ongoing clinical trials targeting somewhat STAT3 involve (i) drugs blocking cell membrane cytokine signaling mainly IL-6 or EGF axis, (ii) drugs inhibiting JAK1/2 intracellular upstream activators of pSTAT3-Y705, and (iii) specific inhibitors of STAT3. Among those drugs, only WP1066, a JAK2 inhibitor, is going to be tested in patients with glioma (NCT01904123). Consequently, it might not show effects on selective inhibition of STAT3. Such effects are expected from STAT3 decoy oligonucleotide [170] , antisense oligonucleotide such as ISIS 481464 (ONIS-STAT3R3) [216] and AZD9150 [217] or direct inhibitors of STAT3-SH2 domain OBP-51602 [218, 219] . However, one of the major drawbacks of STAT3 targeting is the risk of toxicity due to the multiple cellular processes in which STAT3 play a physiological role. Targeting STAT3 for cancer treatment is one of the current challenges, chiefly in glioma. Therefore, identification and validation of new STAT3 inhibitors are needed to pursue the preclinical/clinical testing of broad inhibitors of both phosphorylations. Up to now, pSTAT3-Y05 has been easily blocked by several means but the clinical outcome was not satisfying. There is not yet any clinical trial based on pSTAT3-S727 inhibition. When waiting on the results of ongoing clinical trials (with WP1066 and with STAT3-SH2 inhibitors), it is not less relevant to set on research towards pSTAT3-S727 inhibition because of its involvement in several diseasecarrying mechanisms. We further recommend to examine both pSTAT3-S727 and pSTAT3-Y705 whenever studying the role of STAT3. This will highlight any prognostic or predictive value of STAT3 phosphorylation in glioma or in other diseases. It will moreover provide knowledge to refine STAT3-targeting preclinical and clinical trials.
